Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23485230)

1.

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.

Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, Tolcher AW.

Eur J Cancer. 2013 May;49(8):1799-807. doi: 10.1016/j.ejca.2013.01.003. Epub 2013 Feb 26.

PMID:
23485230
2.

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC.

Ann Oncol. 2013 Mar;24(3):784-91. doi: 10.1093/annonc/mds511. Epub 2012 Oct 26.

3.

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, Baselga J.

Clin Cancer Res. 2011 Oct 1;17(19):6304-12. doi: 10.1158/1078-0432.CCR-10-3336. Epub 2011 Aug 2.

4.

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.

Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S.

Clin Cancer Res. 2011 Feb 15;17(4):871-9. doi: 10.1158/1078-0432.CCR-10-2621. Epub 2010 Dec 22.

5.

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.

Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J.

Br J Cancer. 2008 May 6;98(9):1500-7. doi: 10.1038/sj.bjc.6604347. Epub 2008 Apr 29.

6.

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.

Becerra CR, Conkling P, Vogelzang N, Wu H, Hong S, Narwal R, Liang M, Tavakkoli F, Pandya N.

Cancer Chemother Pharmacol. 2014 Nov;74(5):917-25. doi: 10.1007/s00280-014-2567-9. Epub 2014 Aug 23.

7.

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.

Ernst T, Merx K, Gnad-Vogt U, Lukan N, Kripp M, Schultheis B, Hochhaus A, Hofheinz RD.

Br J Cancer. 2007 Dec 3;97(11):1475-9. Epub 2007 Nov 13.

8.

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.

Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA.

J Clin Oncol. 2010 Oct 10;28(29):4513-20. doi: 10.1200/JCO.2009.26.9696. Epub 2010 Sep 13.

9.

Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.

Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C, Chollet P.

Cancer Biol Ther. 2010 Jan;9(1):8-14. Epub 2010 Jan 21.

10.

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.

Cardoso F, Canon JL, Amadori D, Aldrighetti D, Machiels JP, Bouko Y, Verkh L, Usari T, Kern KA, Giorgetti C, Dirix L.

Breast. 2012 Dec;21(6):716-23. doi: 10.1016/j.breast.2012.09.002. Epub 2012 Sep 27.

PMID:
23022045
11.

A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.

Awada A, Zhang S, Gil T, de Valeriola D, Lalami Y, De Porre P, Piccart-Gebhart MJ.

Curr Med Res Opin. 2007 May;23(5):991-1003.

PMID:
17519066
12.

A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.

Schwartz GH, Jones CB, Garrison M, Patnaik A, Takimoto C, McCreery H, Skinner M, Tolcher AW, Rowinsky EK.

Invest New Drugs. 2004 Nov;22(4):437-48.

PMID:
15292714
13.

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.

Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS.

Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13.

14.

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

Li JL, Zhang XR, Liu JW, Chen ZY, Lin YC, Wang YD, Chen Q, Nan KJ, Song SP, Han FC, Zhu YZ, Li LY, Zheng YH, Chu DT.

Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):309-12. Chinese.

PMID:
16875636
15.

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.

Amadori D, Milandri C, Comella G, Saracchini S, Salvagni S, Barone C, Bordonaro R, Gebbia V, Barbato A, Serra P, Gattuso D, Nanni O, Baconnet B, Gasparini G.

Eur J Cancer. 2011 Sep;47(14):2091-8. doi: 10.1016/j.ejca.2011.05.005. Epub 2011 Jun 12.

PMID:
21665463
16.

Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.

Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L, Tabernero J.

J Clin Oncol. 2011 Oct 1;29(28):3783-90. doi: 10.1200/JCO.2011.34.8888. Epub 2011 Sep 6.

17.

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.

Schmidt M, Rüttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA, Wolf A, Göppel G, Oruzio D, Schlimok G, Steger GG, Wolf C, Eiermann W, Lang A, Schuler M.

Ann Oncol. 2012 Sep;23(9):2306-13. doi: 10.1093/annonc/mdr625. Epub 2012 Feb 21.

18.

A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.

Montemurro F, Choa G, Faggiuolo R, Donadio M, Minischetti M, Durando A, Capaldi A, Vietti-Ramus G, Alabiso O, Aglietta M.

Oncology. 2004;66(1):38-45.

PMID:
15031597
19.

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.

de Jonge MJ, Dumez H, Kitzen JJ, Beuselinck B, Verweij J, Courtney R, Battista A, Brega N, Schöffski P.

Eur J Cancer. 2011 Jun;47(9):1328-35. doi: 10.1016/j.ejca.2011.02.012. Epub 2011 Mar 23.

20.

Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.

Geoerger B, Brasme JF, Daudigeos-Dubus E, Opolon P, Venot C, Debussche L, Vrignaud P, Vassal G.

Eur J Cancer. 2010 Dec;46(18):3251-62. doi: 10.1016/j.ejca.2010.06.005. Epub 2010 Jun 28.

PMID:
20591650
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk